NCT04027439 - Study Evaluating 5 Doses of RPL554 and Placebo in COPD Patients Via a Dry Powder Inhaler | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 10, 2018

Primary Completion Date

May 23, 2019

Study Completion Date

May 23, 2019

Conditions

Pulmonary Disease, Chronic Obstructive

Interventions

DRUG

Part A: RPL554

1 dose of either 50mcg/100mcg/1500mcg/3000mcg/6000mcg or placebo via dry powder inhaler

DRUG

Part B: RPL554

Patients will receive 4 or 5 repeat dose treatments in crossover fashion - doses will be confirmed after Part A

DRUG

Placebos

"Part A: 1 dose of either 50ncg/100ncg/1500ncg/3000ncg/6000ncg or placebo via dry powder inhaler.~Part B: Patients will receive 4 or 5 repeat dose treatments in crossover fashion - doses will be confirmed after Part A."

Trial Locations (1)

29379

VitaLink Research -- Union, Union

All Listed Sponsors

collaborator

Iqvia Pty Ltd

INDUSTRY

lead

Verona Pharma plc

INDUSTRY